{Reference Type}: Journal Article
{Title}: Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
{Author}: Chang EH;Hardy TA;
{Journal}: J Neuroimmunol
{Volume}: 389
{Issue}: 0
{Year}: 2024 Apr 15
{Factor}: 3.221
{DOI}: 10.1016/j.jneuroim.2024.578330
{Abstract}: Siponimod is a sphingosine 1-phosphate receptor (S1P) modulator used to treat secondary progressive multiple sclerosis (SPMS). We report 3 SPMS patients treated with siponimod who developed new or worsening peripheral oedema soon after commencing treatment. In one case, peripheral oedema resulted in immobility. Siponimod-related peripheral oedema deserves wider recognition due to the potential for morbidity and over-investigation. Clinicians should assess for pre-existing oedema and coexisting conditions that may predispose to developing peripheral oedema prior to commencing siponimod.